|

Bria-OTS regimen and CPI (tislelizumab) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • BriaCell Therapeutics Corporation1

Indications

  • Breast Tumor1
  • Malignant Tumor of Breast1
  • Tumors, Breast1
  • Cancer of the Breast1
  • Cancer of Breast1

Santa Monica, California1 trial

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Sarcoma Oncology Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.